Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Ahmad A TarhiniSandra J LeeAik-Choon TanIssam M El NaqaF Stephen HodiLisa H ButterfieldWilliam A LaFramboiseWalter J StorkusArivarasan D KarunamurthyJose R Conejo-GarciaPatrick HwuHoward StreicherVernon K SondakJohn M KirkwoodPublished in: Journal for immunotherapy of cancer (2022)
Patients with MUP and high-risk melanoma had significantly better prognosis and evidence of significantly enhanced immune activation within the TME and the circulation, supporting the designation of MUP as a distinct prognostic marker in patients with high-risk melanoma.
Keyphrases